HbA1c levels (mmol/mol) were also recorded for participants with T2D
doi: 10.1016/j.clinre.2016.11.009 Summary Keywords glucagon-like peptide-1 receptor agonists, metabolic disease, metabolic dysfunction-associated steatotic liver disease, public health, umbrella review Citation Wu H, Zhang Z-H, Ye T, Chen J-N, Tung T-H and Zhu J-S (2026) Efficacy and safety of GLP-1 receptor agonists in patients with metabolic-associated fatty liver diseases: an umbrella review
10.1016/S1074-7613(00)80025-4 31
Supplement Industry: Commonly found in dietary supplements, it is marketed for its potential benefits in boosting energy levels and improving mental clarity
These insights can help contextualize why certain patients respond more robustly to GLP-1 activation, or why dual GIP targeting may align with your genetic profilethough genetic predisposition is not a guarantee of clinical outcome
Vision loss concerns throw natural alternatives in the spotlight Fear of side-effects is often only one among several barriers to taking GLP-1 drugs